Zynerba Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Zynerba Pharmaceuticals Inc (ZYNE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Zynerba Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Zynerba Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (71) | ||||
| High-Confidence Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ZYNE Stock Performance relative to its Competitors
ZYNE Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
| 3 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 4 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 5 | Aclaris Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Zynerba Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Zynerba Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Zynerba Pharmaceuticals Inc | 65.20 | - |
| Vertex Pharmaceuticals Inc | 134,457.22 | 12,587.20 |
| Horizon Therapeutics Public Limited Company | 27,190.33 | 3,643.45 |
| Incyte Corporation | 25,297.38 | 5,361.02 |
| Insmed Inc | 24,804.21 | 1,076.57 |
| Biomarin Pharmaceutical Inc | 11,683.58 | 3,406.61 |
| SUBTOTAL | 261,617.12 | 31,597.97 |
Sign in to see all competitors of Zynerba Pharmaceuticals Inc .
Sources: Zynerba Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Zynerba Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Zynerba Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| The Greater Cannabis Company Inc | Named by the company | 85% |
| Ovid Therapeutics Inc | Named by the company | 85% |
| Puretech Health Plc | Named by the company | 85% |
| Cv Sciences Inc | Named by the company | 85% |
| Gb Sciences Inc | Named by the company | 85% |
| Cnbx Pharmaceuticals Inc | Named by the company | 85% |
| Range Impact Inc | Named by the company | 85% |
| Biomarin Pharmaceutical Inc | Named by the company | 85% |
| Enveric Biosciences Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Zynerba Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Zynerba Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Incyte Corporation | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Precigen Inc | Reportable 100.00 % |
| Avadel Pharmaceuticals Plc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
Zynerba Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Zynerba Pharmaceuticals Inc | 65 | - | -3,131,841 |
| Vertex Pharmaceuticals Inc | 134,457 | 31,079,506 | 10,877,037 |
| Horizon Therapeutics Public Limited Company | 27,190 | 2,802,652 | 336,925 |
| Incyte Corporation | 25,297 | 1,885,028 | 503,438 |
| Insmed Inc | 24,804 | 646,978 | -526,028 |
| Biomarin Pharmaceutical Inc | 11,684 | 1,057,626 | 22,655 |
| PEERS TOTAL | 261,552 | 1,543,849 | 90,175 |
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
Zynerba Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
| Incyte Corporation | United States 93.16 % |
| Insmed Inc | Non-US 12.56 % |
| Ultragenyx Pharmaceutical Inc | North America 43.38 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
Zynerba Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.5x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.4x | 4.5x | -4.1x |
| Return on Equity | -90.03 % | industry aggregate | -100.95 % |
| Return on Invested Capital | -46.41 % | -2.97 % (avg) | -43.44 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Zynerba Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | -21.84 % | -38.94 % | -22.03 % | -31.79 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Zynerba Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 101.0 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-26.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Zynerba Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Zynerba Pharmaceuticals Inc | 4.71 | 5.10 | - |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Horizon Therapeutics Public Limited Company | 2.57 | 4.04 | 0.50 |
| Incyte Corporation | 1.95 | 3.28 | - |
| Insmed Inc | 0.92 | 3.25 | 0.69 |
| Biomarin Pharmaceutical Inc | 1.41 | 4.08 | 0.30 |
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Zynerba Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Zynerba Pharmaceuticals Inc | Q2 2023 | - | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Horizon Therapeutics Public Limited Company | Q2 2023 | +7.7 % | +108.4 % |
| Incyte Corporation | Q1 2026 | +20.9 % | +91.7 % |
| Insmed Inc | Q2 2026 | +393.8 % | - |
| Biomarin Pharmaceutical Inc | Q2 2026 | +19.9 % | -81.4 % |
| PEERS TOTAL | +16.7 % | +54.0 % |
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Zynerba Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Zynerba Pharmaceuticals Inc | Q2 2023 | - | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Horizon Therapeutics Public Limited Company | Q2 2023 | -4.9 % | +81.9 % |
| Incyte Corporation | Q1 2026 | +42.8 % | +379.6 % |
| Insmed Inc | Q2 2026 | +139.4 % | +79.6 % |
| Biomarin Pharmaceutical Inc | Q2 2026 | +35.1 % | +97.2 % |
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
Zynerba Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Zynerba Pharmaceuticals Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Horizon Therapeutics Public Limited Company | 4.81% | 5.71% | 8.54% |
| Incyte Corporation | 21.65% | 27.50% | 29.20% |
| Insmed Inc | - | - | - |
| Biomarin Pharmaceutical Inc | 0.82% | 0.91% | 1.18% |
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Zynerba Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Zynerba Pharmaceuticals Inc | - | - |
| Vertex Pharmaceuticals Inc | 30.72 | 10.68 |
| Horizon Therapeutics Public Limited Company | 62.49 | 7.46 |
| Incyte Corporation | 17.20 | 4.72 |
| Insmed Inc | - | 23.04 |
| Biomarin Pharmaceutical Inc | 166.89 | 3.43 |
| PEERS AVERAGE | 144.70 | 8.28 |
Sign in to see all peers for Zynerba Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.